(CLRB) Cellectar Biosciences, Inc. Business Model Canvas Research

LegoChemBio and PDC Development sit inside Cellectar Biosciences, Inc.’s collaborative development network, helping with discovery and optimization for its PDC oncology platform. This fits a model focused on targeted cancer programs, where external partners shorten research cycles and support pipeline buildout.

• Supports discovery and optimization
• Backs platform-based oncology strategy
• Expands collaborative R&D capacity

Cellectar Biosciences relies on clinical sites to enroll patients and generate data across its Phase 1, Phase 2, and Phase 2b programs, while CROs handle trial operations and CDMOs support drug supply and manufacturing. That setup is central to advancing oncology studies like iopofosine, where execution speed and reliable supply chain control can drive whether a study stays on schedule.

• Clinical sites drive enrollment and endpoints.
• CROs run study ops and data capture.
• CDMOs secure clinical supply and scale-up.

Cellectar Biosciences, Inc. must lock in drug substance and clinical supply for both radioactive and nonradioactive programs, with tight control for iodine-131 assets because I-131 has an 8-day half-life and any delay can cut usable inventory. Reliable GMP manufacturing also keeps trial sites stocked, so enrollment and dosing can continue without supply gaps.

• Secure dual-source supply
• Control I-131 handling tightly
• Protect trial enrollment flow

Cellectar Biosciences builds business development around its phospholipid drug conjugate (PDC) platform by signing collaboration deals with Avicenna Oncology, Orano Med, IntoCell, and LegoChemBio. These partnerships widen pipeline reach, add non-dilutive funding paths, and help spread development risk across multiple programs.

• 4 named collaboration partners
• Expands PDC pipeline reach
• Supports non-dilutive funding

Cellectar Biosciences, Inc. uses a pipeline of CLR 131, CLR 1900, and partnered series as its core resource, with Phase 2, Phase 2b, and Phase 1 programs creating multiple shots on goal. Preclinical assets extend the map beyond today’s trials, giving the Company a longer runway for new indications and partnering.

• CLR 131 and CLR 1900 anchor the pipeline.
• Phase 2, 2b, and 1 programs diversify risk.
• Partnered series add external upside.
• Preclinical assets create longer-term optionality.

Cellectar Biosciences, Inc., founded in 2002 and based in Florham Park, New Jersey, relies on its scientific team and corporate infrastructure to run research, clinical development, and public-company reporting. This base matters because a public biopharma needs both lab execution and governance to move programs through development.

• Founded: 2002
• Headquarters: Florham Park, New Jersey
• Supports research execution
• Enables public-company operations

Cellectar Biosciences, Inc. can grow the PDC platform through both in-house programs and named partnerships, which helps push new series into development while splitting cost and risk. This matters in a capital-heavy space where one late-stage oncology trial can cost tens of millions of dollars, so external collaboration can speed innovation without fully funding each asset alone.

• Expand PDC into new series
• Share development costs and risk
• Speed pipeline progress

Cellectar Biosciences, Inc. uses CLR 131, an iodine-131-based investigational therapy, to stand out from standard oncology developers. Radiopharmaceutical design lets the company target specialized cancer markets with a clearer precision-medicine story than broad small-molecule or antibody drugs.

• CLR 131 uses iodine-131
• Investigational, not approved
• Supports niche cancer positioning

Cellectar Biosciences' regulatory communication is a core customer link: the Company works with the FDA and other agencies throughout development, and that feedback shapes trial design, endpoints, and submission plans for iopofosine I 131. This ongoing dialogue is central to moving programs from early data to later-stage review.

• Agency feedback guides trial design
• Submission strategy changes with updates
• Regulatory ties support late-stage progress

Cellectar Biosciences, Inc. reaches patients mainly through clinical trials, so the relationship is built on informed consent, safety checks, and site coordination rather than direct sales. As of its latest filings, the Company was still advancing patient enrollment across multiple studies, with support tied to protocol rules, adverse-event monitoring, and investigator sites.

• Clinical-trial only patient access
• Informed consent before dosing
• Ongoing safety monitoring
• Site-led protocol coordination

Business Development Outreach is Cellectar Biosciences, Inc.'s direct channel for licensing and collaboration talks with biotech and pharma partners, and it is central to platform partnering around the PDC series portfolio. The company has built this channel around pipeline deals, with 1 lead partnership path per asset class, so each PDC program can be packaged for a fit-for-purpose alliance.

• Pursues direct biotech and pharma licensing
• Supports platform-level partnering
• Most relevant for the PDC series portfolio

Cellectar Biosciences, Inc. uses investor relations and capital markets to reach analysts and investors, which is critical for a development-stage Company funding R&D-heavy programs. This channel supports equity and other financing needs, since clinical-stage biotech firms often depend on external capital to advance trials and pipeline work.

• Targets investors and analysts
• Supports R&D funding
• Builds market trust

CLR 131 is in Phase 1 evaluation for pediatric cancers, so Cellectar Biosciences, Inc. targets a medically fragile segment with high unmet need. Pediatric oncology can benefit from targeted investigational therapies because they may improve precision while limiting harm to healthy tissue.

• Phase 1 pediatric cancer testing
• High unmet medical need
• Targeted therapy fit

Biopharma collaboration partners are a key customer segment for Cellectar Biosciences, Inc. Named counterparties include Avicenna Oncology, Orano Med, IntoCell, and LegoChemBio, giving the company four visible platform buyers that pay for access, know-how, and co-development support beyond direct clinical use.

This segment helps spread Cellectar Biosciences, Inc. across licensing and partnership income, not just drug sales, and it can shorten the path to monetizing its phospholipid-drug conjugate platform.

• 4 named partners
• Platform access buyers
• Development know-how demand

Cellectar Biosciences, Inc. carries fixed public-company overhead in management, finance, legal, investor relations, and headquarters operations, so General and Administrative stays a steady cash drain even before product revenue scales. In its latest reported filings, this cost line remained one of the core operating burdens tied to SEC reporting, audit, and board support.

• Fixed HQ and compliance costs
• Management, legal, IR, finance
• Scales slower than R&D

Regulatory, IP, and partnering costs stay material for Cellectar Biosciences, Inc. because each IND/clinical filing, patent family, and alliance review adds recurring cash use. In the latest reported year, the company posted operating losses and continued to fund development plus outside collaboration work, so these costs directly support platform protection and pipeline progress.

• Regulatory filings drive ongoing spend
• Patents protect the platform
• Partner admin supports shared development

Royalties from partnered programs can become a future cash stream if Cellectar Biosciences, Inc.’s partners win approval and launch the asset. The upside is tied to partner sales, so royalty income can arrive without Cellectar Biosciences, Inc. carrying full commercial costs; for example, a 1% royalty on $100 million in partner sales would equal $1 million.

• Needs partner approval first
• Sales drive royalty size
• Adds upside beyond R&D

If CLR 131 or another phospholipid drug conjugate wins approval, Cellectar Biosciences, Inc. could shift from zero commercial product revenue to direct sales, the highest-value stream in its model. For now, it is still a development-stage company, with no approved products and no recurring product revenue.

• No product sales yet
• Approval would unlock direct revenue
• CLR 131 is the key value driver